In this current study, we also used patient-derived KU-CSLC cells, which have high drug-resistance, stemness, tumorigenic, and aggressive cancer stem cell-like cell properties, and a commercially available aggressive MDA-MB231 cell line to identify the role of KRT19 in cancer reprogramming and drug sensitivity. The gene discussed is KRT19; the disease is cancer.